BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30383218)

  • 1. Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
    Colombo C; De Leo S; Di Stefano M; Vannucchi G; Persani L; Fugazzola L
    J Clin Endocrinol Metab; 2019 Mar; 104(3):779-784. PubMed ID: 30383218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event.
    Monti S; Presciuttini F; Deiana MG; Motta C; Mori F; Renzelli V; Stigliano A; Toscano V; Pugliese G; Poggi M
    Thyroid; 2022 Jan; 32(1):46-53. PubMed ID: 34663079
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex.
    Colombo C; Ceruti D; Succi M; De Leo S; Trevisan M; Moneta C; Fugazzola L
    Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare complications of multikinase inhibitor treatment.
    Pitoia F; Schmidt A; Bueno F; Abelleira E; Jerkovich F
    Arch Endocrinol Metab; 2018; 62(6):636-640. PubMed ID: 30624504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
    Hu MI; Elisei R; Dedecjus M; Popovtzer A; Druce M; Kapiteijn E; Pacini F; Locati L; Krajewska J; Weiss R; Gagel RF
    Endocr Relat Cancer; 2019 Feb; 26(2):241-250. PubMed ID: 30557850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
    Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
    Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
    Brose MS; Panaseykin Y; Konda B; de la Fouchardiere C; Hughes BGM; Gianoukakis AG; Joo Park Y; Romanov I; Krzyzanowska MK; Leboulleux S; Binder TA; Dutcus C; Xie R; Taylor MH
    J Clin Endocrinol Metab; 2022 Feb; 107(3):776-787. PubMed ID: 34664662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 15. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies for thyroid cancer.
    Krajewska J; Jarzab B
    Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.
    Verburg FA; Amthauer H; Binse I; Brink I; Buck A; Darr A; Dierks C; Koch C; König U; Kreissl MC; Luster M; Reuter C; Scheidhauer K; Willenberg HS; Zielke A; Schott M
    Horm Metab Res; 2021 Mar; 53(3):149-160. PubMed ID: 33652491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
    Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
    Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.